# EditForce

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/editforce

- Industry: Biotechnology
- Headquarters: Fukuoka-shi, Japan
- Website: www.editforce.co.jp/
- Total disclosed funding: $39M
- Latest round: Series D (May 22, 2023)
- Investors on record: 14

## About

Based in Japan, EditForce Inc. specializes in RNA editing technologies, providing innovative solutions for pharmaceuticals, agriculture, and industrial applications.EditForce Inc. was founded in 2015 in Fukuoka-shi, Japan, focusing on advanced RNA editing technologies. The company has successfully completed 4 deals, with its latest funding round being Series D, which raised JPY 2.1 billion on May 22, 2023, involving investors such as Regional Economy Vitalization Corporation of Japan (REVIC) and Fukuoka Jisho. The company was formed by a team with extensive backgrounds in biotechnology, although specific details about the founder’s history are not provided.EditForce Inc. specializes in innovative RNA editing technologies, which serve as the foundation for their core offerings in the fields of pharmaceuticals, agriculture, and various industrial applications. The company has developed a unique gene manipulation technique based on the PPR (Pentatricopeptide Repeat) protein discovered in plants, differentiating it from traditional RNA editing methods. Their primary focus is on drug development, where they aim to establish effective treatments for various diseases by leveraging their advanced editing capabilities. These products are targeted at a diverse client base that includes pharmaceutical companies, research institutions, and agricultural firms across global markets, such as North America, Europe, and Asia. EditForce’s commitment to pioneering a new standard in RNA editing positions them to address significant challenges in healthcare and agriculture, creating impactful solutions tailored to end-user needs.EditForce's revenue model is grounded in partnerships and collaborations with pharmaceutical companies and research institutions, which utilize their proprietary RNA editing technologies in drug development and research initiatives. These transactions are structured as B2B agreements, where EditForce provides access to its technology through licensing arrangements or collaborative research contracts. The company focuses on creating value through strategic alliances, promoting long-term relationships that facilitate ongoing development and commercialization of their innovative solutions. Specific pricing plans for individual services or products are determined based on the nature of the collaboration and the scope of the projects, ensuring tailored financial arrangements that align with client objectives. The company's flagship offerings in RNA editing technology exemplify their commitment to advancing medical and agricultural practices, reflecting their strategic vision for generating revenue in key sectors.In May 2023, EditForce Inc. raised JPY 2.1 billion in Series D funding, which will be utilized for promotion, technology improvement, and research and development initiatives. The company plans to launch new RNA editing products targeting specific applications in pharmaceuticals and agriculture, with expected releases in the next 12-18 months. Additionally, EditForce aims to expand its market presence into Europe and North America by the end of 2025, leveraging its recent funding to strengthen its operations and establish strategic partnerships in these regions.

## Funding rounds

- Series D, May 22, 2023, $15M — University of Tokyo Edge Capital Partners, MP Healthcare Venture Management, SMBC Venture Capital, Regional Economy Vitalization Corporation of Japan (REVIC), FFG Venture Business Partners, Newton Biocapital Partners, Fukuoka Jisho
- Series C, Jun 30, 2021, $12M — University of Tokyo Edge Capital Partners, MP Healthcare Venture Management, ITOCHU Technology Ventures, Global Brain, FFG Venture Business Partners, Newton Biocapital Partners, Yoshimei Co., Ltd.
- Series B, Mar 1, 2019, $10M — University of Tokyo Edge Capital Partners, ITOCHU Technology Ventures, Japan Science and Technology Agency, QB Capital, Newton Biocapital Partners, K4 Ventures, KISCO
- Series A, Mar 2, 2016, $1.5M — University of Tokyo Edge Capital Partners, KISCO

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B, Series C, Series D
- KISCO — Series A, Series B
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series B, Series C
- Japan Science and Technology Agency — Series B
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series B
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series B, Series C, Series D
- K4 Ventures (https://capitalatlas.ai/funds/k4-ventures) — Series B
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series C, Series D
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series C
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series C, Series D
- Yoshimei Co., Ltd. — Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series D
- Regional Economy Vitalization Corporation of Japan (REVIC) — Series D
- Fukuoka Jisho — Series D